An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. (14th November 2018)

• Record Type: Journal Article
• Authors: Verdura, Sara; Cuyàs, Elisabet; Lozano-Sánchez, Jesús; Bastidas-Velez, Cristian; Llorach-Parés, Laura; Fernández-Arroyo, Salvador; Hernández-Aguilera, Anna; Joven, Jorge; Nonell-Canals, Alfons; Bosch-Barrera, Joaquim; Martin-Castillo, Begoña; Vellon, Luciano; Sanchez-Martinez, Melchor; Segura-Carretero, Antonio; Menendez, Javier A
• Is Part Of: Carcinogenesis. Volume 40:Number 1(2019)
• Page Start: 27
• Page End: 40
• Publication Date: 2018-11-14
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgy159
• Languages: English
• ISSNs: 0143-3334

Abstract

Abstract : An olive oil phenolic is a naturally occurring chemotype of mutant IDH1-targeted inhibitors that could be employed as a scaffold for drug discovery. Abstract: Mutations in the isocitrate dehydrogenase 1 (IDH1) gene confer an oncogenic gain-of-function activity that allows the conversion of α-ketoglutarate (α-KG) to the oncometabolite R-2-hydroxyglutarate (2HG). The accumulation of 2HG inhibits α-KG-dependent histone and DNA demethylases, thereby generating genome-wide hypermethylation phenotypes with cancer-initiating properties. Several chemotypes of mutant IDH1/2-targeted inhibitors have been reported, and some of them are under evaluation in clinical trials. However, the recognition of acquired resistance to such inhibitors within a few years of clinical use raises an urgent need to discover new mutant IDH1 antagonists. Here, we report that a naturally occurring phenolic compound in extra-virgin olive oil (EVOO) selectively inhibits the production of 2HG by neomorphic IDH1 mutations. In silico docking, molecular dynamics, including steered simulations, predicted the ability of the oleoside decarboxymethyl oleuropein aglycone (DOA) to preferentially occupy the allosteric pocket of mutant IDH1. DOA inhibited the enzymatic activity of recombinant mutant IDH1 (R132H) protein in the low micromolar range, whereas >10-fold higher concentrations were required to inhibit the activity of wild-type (WT) IDH1. DOA suppressed 2HG overproduction in engineered human cells expressing a heterozygous IDH1-R132H mutation. DOA restored the 2HG-suppressed activity of histone demethylases as it fully reversed the hypermethylation of H3K9me3 in IDH1-mutant cells. DOA epigenetically restored the expression of PD-L1, an immunosuppressive gene silenced in IDH1 mutant cells via 2HG-driven DNA hypermethylation. DOA selectively blocked colony formation of IDH1 mutant cells while sparing WT IDH1 isogenic counterparts. In sum, the EVOO-derived oleoside DOA is a new, naturally occurring chemotype of mutant IDH1 inhibitors.